Who are WHO-recommended SOC Itraconazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loceryl NL 12 weeks, Topical Clotrimazole cream, Clotrimazole 1%, Bifonazole Cream, Topical ketoconazole 2% cream, Voriconazole low dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/who-recommended-soc-itraconazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

WHO-recommended SOC Itraconazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WHO-recommended SOC Itraconazole (WHO-recommended SOC Itraconazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal. Area: Infectious Diseases.

phase 3 Triazole antifungal Lanosterol 14α-demethylase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

WHO-recommended SOC Itraconazole (WHO-recommended SOC Itraconazole) — University of Minnesota. Itraconazole inhibits the synthesis of ergosterol, an essential component of fungal cell membranes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
WHO-recommended SOC Itraconazole TARGET	WHO-recommended SOC Itraconazole	University of Minnesota	phase 3	Triazole antifungal	Lanosterol 14α-demethylase
Loceryl NL 12 weeks	Loceryl NL 12 weeks	Galderma R&D	marketed	Allylamine antifungal	Lanosterol 14α-demethylase (CYP51)
Topical Clotrimazole cream	Topical Clotrimazole cream	Hayat Abad Medical Complex, Peshawar	marketed	Imidazole antifungal	Fungal lanosterol 14α-demethylase (CYP51)
Clotrimazole 1%	Clotrimazole 1%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Fungal cytochrome P450 (lanosterol 14α-demethylase)
Bifonazole Cream	Bifonazole Cream	Galderma R&D	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Topical ketoconazole 2% cream	Topical ketoconazole 2% cream	PAEC General Hospital, Islamabad	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
Voriconazole low dose	Voriconazole low dose	Manjunath Prakash Pai	marketed	Triazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal class)

University of Maryland, Baltimore · 3 drugs in this class
Manjunath Prakash Pai · 2 drugs in this class
Pfizer · 2 drugs in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
University of California, San Francisco · 1 drug in this class
University of Minnesota · 1 drug in this class
Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). WHO-recommended SOC Itraconazole — Competitive Intelligence Brief. https://druglandscape.com/ci/who-recommended-soc-itraconazole. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab